Results 261 to 270 of about 1,839,456 (290)

Lesional volume in the prediction of clinically significant prostate cancer. [PDF]

World J Surg Oncol
Brodie B, Peh DYY, Tan YG, Law YM, Tay KJ, Cheng CWS, Ho HSS, Yuen JSP, Lee AYM, Chen K.   +9 more
europepmc   +1 more source

Comparative Analysis of Clinical Outcomes and Financial Aspects of Phototherapies and Immunotherapy for Cancer

Advanced Science, EarlyView.
This review compares clinical outcomes, translational progress, and global funding trends across cancer phototherapies—photodynamic, photothermal, and photoimmunotherapy—and conventional immunotherapy. It highlights differences in treatment efficacy, clinical trial status, financial investment, and regulatory challenges, providing a comprehensive ...
Deepak S. Chauhan, Kun Shao, Roopa Hebbandi Nanjundappa, Daniel‐Jiajun Yu, Marianne Stanford, Huile Gao, Channakeshava Sokke Umeshappa   +6 more
wiley   +1 more source

Prostate cancer inducing secondary linitis plastica of the rectum: a rare case report and literature review. [PDF]

Front Oncol
Zhang D, Li J, Sun T, Zhang L, Wang L, Gan Q, Xing X, Zhang Y, Wang Y, Liao D, Li J.   +10 more
europepmc   +1 more source

Targeting Intratumoral Copper Inhibits Tumor Progression via p62‐Mediated EZH2 Degradation and Potentiates Anti‐PD‐1 Immunotherapy in Oral Squamous Cell Carcinoma

Advanced Science, EarlyView.
The authors find that by targeting intratumoral copper, they can enhance p62‐mediated ubiquitination of EZH2 at the Ub‐K63 site by suppressing copper binding to SMURF2, an E3 ligase of EZH2, leading to its autophagic degradation. This mechanism suppressed OSCC progression and potentiated anti‐PD‐1 immunotherapy, highlighting a potential new therapeutic
Xiaohu Lin, Wanling Chen, Bo Li, Zhang Zhao, Zhonglin Yu, Xu‐Yun Zhao, Xuan Zhou, Zhien Feng, Chengzhong Lin, Wei Cao   +9 more
wiley   +1 more source

Copper death combination therapy: the innovative frontier and challenges in prostate cancer treatment. [PDF]

Cancer Biol Ther
He JW, Li PZ, Huang ZX.
europepmc   +1 more source

Irisin Attenuates Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension via Ubiquitin‐Mediated Regulation of ENO1

Advanced Science, EarlyView.
Irisin is a crucial plasma biomarker and promising therapeutic target that reflects disease severity, pulmonary vascular remodeling status and clinical outcome in patients with pulmonary arterial hypertension (PAH). As a novel protective factor, irisin is downregulated in PAH. By ubiquitination, irisin promotes Enolase 1 degradation and suppresses cell
Na Sun, Yong‐Bing Wang, Jing Huang, Run‐Wei Deng, Hui‐Yu He, Lei Gao, Xuan Gao, You‐Li Fan, Yan Cong, Yao‐Lei Guo, Yi‐Qiang Chen, Gui‐Jia Wang, Shao‐Hong Fang, Xia Gu, Bo Yu, Bing‐Xiang Wu   +15 more
wiley   +1 more source

Treatment Intensification Prior to Radical Prostatectomy for Clinically Localized Prostate Cancer. [PDF]

Cancers (Basel)
Perez Kerkvliet CJ, Leong JY, Thompson RAM, Zarrabi KK, Kelly WK, Lallas C, Gomella L, Shah M.   +7 more
europepmc   +1 more source

An Engineered Soluble Single‐Chain TCR Engager for KRAS‐G12V Specific Tumor Immunotherapy

Advanced Science, EarlyView.
This study develops a dimeric T cell receptor engager protein specific for tumor KRAS‐G12V mutation. The engager proteins are capable of mediating the formation of synapse between T cell and tumor cell and demonstrate substantial tumor suppression efficacy.
Keke Ma, Jie Wang, Min Jiang, Juanhua He, Fangyang Li, Dan Lu, Chao Su, Yan Chai, Wenjing Jin, Yu Chen, Catherine W.H. Zhang, Xiaopeng Ma, Hui Tan, George F. Gao, Shuguang Tan   +14 more
wiley   +1 more source

Controversies in metastatic hormone-sensitive prostate cancer. [PDF]

Cancer
Tsung I, Yentz SE, Reichert ZR.
europepmc   +1 more source